SCHEMBL7216599

SCHEMBL7216599

Oc1nc(SCCOc2ccccc2)nc(-c2ccncc2)c1-c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.47
MAPK13 O15264 5/20 0.47
MAPK12 P53778 5/20 0.47
MAPK11 Q15759 5/20 0.47
LMNA P02545 2/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.40
MAPK10 P53779 2/20 0.40
HTT P42858 1/20 0.38
HIF1A Q16665 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALOX5 P09917 2/20 0.38
SRC P12931 1/20 0.38
BRAF P15056 1/20 0.38
KDR P35968 1/20 0.38
GCGR P47871 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7215918 0.85 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL7211830 0.82 MAPK14 (0.40) MAPK14MAPK13MAPK12MAPK11MAPK10
SCHEMBL7211714 0.82 MAPK14 (0.52) MAPK14MAPK13MAPK12MAPK11MAPK10
SCHEMBL6933682 0.78 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11LMNA
SCHEMBL7212575 0.72 MAPK14 (0.45) MAPK14MAPK13MAPK12MAPK11RAB9A
SCHEMBL1387650 0.68 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL7215276 0.65 MAPK14 (0.52) MAPK14MAPK13MAPK12MAPK11MAPK10
SCHEMBL10345731 0.65 ALDH1A1 (0.51) LMNAALDH1A1HTTTDP1MAPT
SCHEMBL7216217 0.64 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL27522556 0.64 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1314731-A2 Substituted pyrimidine compounds and their use AMGEN INC. (US) 2003-05-28 EP claimed
US-20030069425-A1 Substituted pyrimidine compounds and methods of use AMGEN INC. 2003-04-10 US claimed
US-6410729-B1 ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS AMGEN INC. 2002-06-25 US claimed
EP-0948497-A2 SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE Amgen inc. (US) 1999-10-13 EP claimed
WO-1998024782-A2 SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 WO claimed
EP-1314732-A2 Substituted pyrimidine compounds and their use AMGEN INC. (US) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069425-A1 Substituted pyrimidine compounds and methods of use DPYD, IL6, IL1B MAPK14 2062/4885MAPK13 2250/4885MAPK12 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.